Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion

Table 2

Group comparisons between low responder and responder to ranibizumab treatment.

	Mean age	% CRVO	% BRVO	VA baseline	VA after loading phase	VA end of study	CRT baseline	CRT after loading phase	CRT end of study	Number of injections
Low-responder group VA month 4		58	42
Responder group VA month 4		48	52
Low-responder group VA end-of study		50	50
Responder group VA end-of-study		50	50
Low-responder group CRT month 4		47	53
Responder group CRT month 4		54	46
Low-responder group CRT end-of study		60	40
Responder group CRT end-of-study		53	47

injections: LR versus R VA loading phase: 0.0067.
VA: LR versus R VA loading phase: 0.027.
VA: LR versus R VA end-of-study: 0.0173.
CRT: LR versus R VA loading phase: 0.0216.
CRT: LR versus R VA end-of-study: 0.0443.
CRT: LR versus R CRT loading phase: 0.0083.
CRT: LR versus R CRT end of study: 0.05.
VA: LR versus R VA loading phase: 0.0061.
phase VA: LR versus R VA: 0.031.
phase VA: LR versus R CRT loading phase: 0.0001.
phase VA: LR versus R CRT end of study: 0.013.
phase CRT: LR versus R VA loading phase: 0.0003.
phase CRT: LR versus R VA end of study: 0.001.
phase CRT: LR versus R: 0.0001.
Corresponding values (letter coded): LR = low-responder; R = responder; CRT = central retinal thickness; VA = visual acuity.
Values are given ± standard deviation. All nonlettered values showed no significant differences.